v3.26.1
Convertible Promissory Notes - Additional Information (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended
Jan. 31, 2025
USD ($)
Nov. 30, 2024
USD ($)
Oct. 31, 2024
USD ($)
May 31, 2024
USD ($)
Mar. 31, 2024
USD ($)
Mar. 31, 2026
USD ($)
$ / shares
shares
Mar. 31, 2025
USD ($)
Mar. 31, 2024
USD ($)
Dec. 31, 2024
Short-Term Debt [Line Items]                  
Issuance of conversion of convertible promissory notes             $ 3,695    
Kalaris Therapeutics, Inc. | Series B-2 Redeemable Convertible Preferred Stock                  
Short-Term Debt [Line Items]                  
Debt instrument, converted ratio           1      
Maximum | Kalaris Therapeutics, Inc.                  
Short-Term Debt [Line Items]                  
Issuance of conversion of convertible promissory notes     $ 7,500            
Probability of Achievement | Minimum                  
Short-Term Debt [Line Items]                  
Tranche liability                 0
Probability of Achievement | Maximum                  
Short-Term Debt [Line Items]                  
Tranche liability                 0.80
Discount Rate                  
Short-Term Debt [Line Items]                  
Tranche liability                 0.09
2024 Convertible Promissory Note                  
Short-Term Debt [Line Items]                  
Outstanding principal amount           $ 10,000      
Interest rate         10.00%     10.00%  
Aggregate advance       $ 10,000 $ 5,000        
Maturity date         2025-03        
Estimated fair value         $ 12,100     $ 12,100  
Change in the fair value of derivative liability             500 500  
Loss on issuance of convertible promissory notes             (200)    
Interest expense             800    
Contractual interest expense             200    
Amortization of debt discount             600    
Total premium on debt         2,100        
Accrued interest           $ 900      
Common shares issued for conversion of debt | shares           1,757,951      
Conversion price per share | $ / shares           $ 6.2      
2024 Convertible Promissory Note | Kalaris Therapeutics, Inc.                  
Short-Term Debt [Line Items]                  
Debt instrument, issued, principal amount $ 3,750                
2024 Convertible Promissory Note | Maximum                  
Short-Term Debt [Line Items]                  
Outstanding principal amount         $ 10,000     $ 10,000  
2024 Bridge Notes                  
Short-Term Debt [Line Items]                  
Outstanding principal amount   $ 5,000       $ 10,000      
Interest rate   8.00%              
Maturity date     2025-05            
Change in the fair value of derivative liability             500    
Recognized gain for change in fair value of tranche liability             400    
Total fair value at issuance of derivative instrument     $ 1,000            
Accrued interest           $ 300      
Common shares issued for conversion of debt | shares           1,660,888      
Conversion price per share | $ / shares           $ 6.2      
Debt instrument, issued, principal amount   $ 1,000 9,000            
Additional draw up amount   $ 15,000              
2024 Bridge Notes | Maximum                  
Short-Term Debt [Line Items]                  
Outstanding principal amount     15,000            
Debt instrument, issued, principal amount     25,000            
2025 Bridge Notes                  
Short-Term Debt [Line Items]                  
Outstanding principal amount 3,900         $ 3,750      
Change in the fair value of derivative liability             200    
Total fair value at issuance of derivative instrument $ 200                
Accrued interest           $ 100      
Per share price paid by investors 8.50%                
2025 Bridge Notes | Redeemable Convertible Preferred Stock                  
Short-Term Debt [Line Items]                  
Difference between the fair value at the issuance date and the principal amount of the note $ 200                
2025 Bridge Notes | Series B-2 Redeemable Convertible Preferred Stock                  
Short-Term Debt [Line Items]                  
Outstanding principal amount $ 3,750                
Common shares issued for conversion of debt | shares           794,499      
Conversion price per share | $ / shares           $ 4.7851      
2025 Bridge Notes | Minimum                  
Short-Term Debt [Line Items]                  
Expected term (in years) 2 months 12 days                
2025 Bridge Notes | Maximum                  
Short-Term Debt [Line Items]                  
Expected term (in years) 3 months 18 days                
2025 Bridge Notes | Probability of Achievement | Minimum                  
Short-Term Debt [Line Items]                  
Tranche liability 0.20                
2025 Bridge Notes | Probability of Achievement | Maximum                  
Short-Term Debt [Line Items]                  
Tranche liability 0.80                
2025 Bridge Notes | Tranche | Series B-2 Redeemable Convertible Preferred Stock                  
Short-Term Debt [Line Items]                  
Additional draw up amount $ 5,000                
2025 Bridge Notes | First and Second Tranches | Series B-2 Redeemable Convertible Preferred Stock                  
Short-Term Debt [Line Items]                  
Additional draw up amount 3,750                
2025 Bridge Notes | Third Tranches | Series B-2 Redeemable Convertible Preferred Stock                  
Short-Term Debt [Line Items]                  
Additional draw up amount 7,500                
2024 Bridge Notes and 2025 Bridge Notes                  
Short-Term Debt [Line Items]                  
Interest expense             600    
Contractual interest expense             200    
Amortization of debt discount             $ 400    
January 2025 AlloVir Convertible Promissory Note                  
Short-Term Debt [Line Items]                  
Outstanding principal amount $ 3,750                
AlloVir Note | Kalaris Therapeutics, Inc.                  
Short-Term Debt [Line Items]                  
Common shares issued for conversion of debt | shares           160,165      
AlloVir Note | Maximum                  
Short-Term Debt [Line Items]                  
Issuance of conversion of convertible promissory notes     $ 7,500